NCT02744287 2026-02-23
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
Regeneron Pharmaceuticals
Phase 1 Terminated
Regeneron Pharmaceuticals
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine